Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series.
Subcutaneous implantable venous access devices (IVADs) are commonly used in oncology practice. They facilitate the administration of chemotherapy, fluids and blood products. The incidence of IVAD-related complications is not uncommon, and includes infection, thrombosis and bleeding. IVAD erosion through the skin has been reported secondary to infection or inexperienced handling. We report three cases of IVAD erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy. Anti-vascular endothelial growth factor agents are increasingly used in the treatment of solid tumors. This class of drugs has been associated with delayed wound healing and thromboembolism. To our knowledge, this is the first case series of IVAD erosion through skin, in patients receiving such therapy.
Almhanna
Khaldoun
K
Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA.
Pelley
Robert J
RJ
Thomas Budd
G
G
Davidson
Jon
J
Moore
Halle C F
HC
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000628:therapy; D002405:Catheterization, Central Venous / Q000009:adverse effects* / Q000295:instrumentation; D002408:Catheters, Indwelling / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D012883:Skin Ulcer / Q000209:etiology*; D040521:Subcutaneous Tissue / Q000601:surgery; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab